Skip to Primary Navigation

Skip to main content

Pharma speaker bureau alleged to cross into FCA territory, settles for $13.6m

A photo of a busy restaurant with brick walls and many lights
Meals at expensive restaurants are said to have been used as inducements. Photo by Daniel Zuchnik/Getty Images for NYCWFF

Kevin Kinsella

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The agreement resolves allegations into whether the company’s speaker programs and meals for physicians violated anti-kickback laws.

Takeda Pharmaceuticals USA has agreed to pay $13.6m to resolve federal allegations that it violated the Anti‑Kickback Statute (AKS) by providing improper payments and benefits – such as lavish meals – to healthcare providers to encourage prescriptions of its antidepressant Trintellix, according to the US Department of Justice (DOJ).

Takeda is

, , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience